Limits...
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma

View Article: PubMed Central - PubMed

ABSTRACT

Survival after sorafenib initiation in newly diagnosed Medicare beneficiaries with hepatocellular carcinoma (HCC) is exceptionally short, suggesting that trial results are not generalizable to all HCC patients. The downsides of sorafenib use—high drug-related symptom burden and high drug cost—must be considered in light of this minimal benefit.

No MeSH data available.


Related in: MedlinePlus

Effectiveness of sorafenib in clinically relevant subgroups. The risk ratios for mortality shown with 95% confidence intervals at 3 months from the 60-day landmark (the time of maximal sorafenib benefit) are shown for the strata of age, Charlson Comorbidity Index, number of liver comorbidities, receipt of prior AFP screening, and tumor extent in the propensity score-matched cohort.Abbreviation: AFP, α-fetoprotein.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC5016063&req=5

Figure 3: Effectiveness of sorafenib in clinically relevant subgroups. The risk ratios for mortality shown with 95% confidence intervals at 3 months from the 60-day landmark (the time of maximal sorafenib benefit) are shown for the strata of age, Charlson Comorbidity Index, number of liver comorbidities, receipt of prior AFP screening, and tumor extent in the propensity score-matched cohort.Abbreviation: AFP, α-fetoprotein.

Mentions: In an exploratory subgroup analysis limited by small sample size, the effectiveness of initial sorafenib appeared greatest in patients with the lowest burden of disease (multiple tumors without vascular invasion or extrahepatic spread; 3-month aRR, 0.70 [95% CI, 0.51–0.95]); it was least pronounced in patients age <65 years (e.g., disabled beneficiaries), and patients with more liver comorbidity (Fig. 3).


Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
Effectiveness of sorafenib in clinically relevant subgroups. The risk ratios for mortality shown with 95% confidence intervals at 3 months from the 60-day landmark (the time of maximal sorafenib benefit) are shown for the strata of age, Charlson Comorbidity Index, number of liver comorbidities, receipt of prior AFP screening, and tumor extent in the propensity score-matched cohort.Abbreviation: AFP, α-fetoprotein.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC5016063&req=5

Figure 3: Effectiveness of sorafenib in clinically relevant subgroups. The risk ratios for mortality shown with 95% confidence intervals at 3 months from the 60-day landmark (the time of maximal sorafenib benefit) are shown for the strata of age, Charlson Comorbidity Index, number of liver comorbidities, receipt of prior AFP screening, and tumor extent in the propensity score-matched cohort.Abbreviation: AFP, α-fetoprotein.
Mentions: In an exploratory subgroup analysis limited by small sample size, the effectiveness of initial sorafenib appeared greatest in patients with the lowest burden of disease (multiple tumors without vascular invasion or extrahepatic spread; 3-month aRR, 0.70 [95% CI, 0.51–0.95]); it was least pronounced in patients age <65 years (e.g., disabled beneficiaries), and patients with more liver comorbidity (Fig. 3).

View Article: PubMed Central - PubMed

ABSTRACT

Survival after sorafenib initiation in newly diagnosed Medicare beneficiaries with hepatocellular carcinoma (HCC) is exceptionally short, suggesting that trial results are not generalizable to all HCC patients. The downsides of sorafenib use&mdash;high drug-related symptom burden and high drug cost&mdash;must be considered in light of this minimal benefit.

No MeSH data available.


Related in: MedlinePlus